1. Home
  2. AXTI vs NRIX Comparison

AXTI vs NRIX Comparison

Compare AXTI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AXT Inc

AXTI

AXT Inc

HOLD

Current Price

$71.36

Market Cap

3.1B

Sector

Technology

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$26.72

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXTI
NRIX
Founded
1986
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.5B
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
AXTI
NRIX
Price
$71.36
$26.72
Analyst Decision
Hold
Strong Buy
Analyst Count
3
12
Target Price
$50.50
$30.50
AVG Volume (30 Days)
11.5M
999.6K
Earning Date
04-30-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.16
N/A
Revenue
$99,361,000.00
$76,987,000.00
Revenue This Year
$44.70
N/A
Revenue Next Year
$42.23
$48.05
P/E Ratio
$461.56
N/A
Revenue Growth
31.09
99.31
52 Week Low
$2.68
$8.20
52 Week High
$143.16
$28.23

Technical Indicators

Market Signals
Indicator
AXTI
NRIX
Relative Strength Index (RSI) 49.50 64.21
Support Level $65.02 $14.63
Resistance Level $71.49 N/A
Average True Range (ATR) 10.26 0.98
MACD 0.30 0.02
Stochastic Oscillator 26.80 75.95

Price Performance

Historical Comparison
AXTI
NRIX

About AXTI AXT Inc

AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: